irinotecan相关论文
...
The efficacy and safety of irinotecan ± bevacizumab and oxaliplatin ± bevacizumab in metastatic colo
Objective Background: Irinotecan-based and oxaliplatin-based regimens are available for the treatment of metastatic colo......
The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for meta
...
Anlotinib and Irinotecan for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy:a M
...
Objective: The incidence of colorectal cancer ranked the third in men and the second in women.High aggressiveness of col......
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in can
Aim: A prodrug, irinotecan, is a semisynthetic derivative of camptothecin.It inhibits topoisomerase Ⅰ and is used as th......
Bevacizumab alone and in combination with Irinotecan in recurrent glioblastoma multiforme: A meta-an
The combination of Bevacizumab and Irinotecan is a new chemotherapy for recurrent glioblastoma multiforme (GBM).Recent p......
...
UGT1A1*6,UGT1A7*3 and UGT1A9*1b Polymorphismsare predictive markers forsevere toxicity in Chinese me
Irinotecan-induced severeneutropenia and diarrhea which are still unpredictable hasrestrained the dose and clinical effi......
The living organisms respond differently to the enantiomers of various drugs.Irinotecan is an important candidate in the......
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for adva
...
目的探讨尿苷二磷酸葡萄糖醛酸转移酶1A1(UGT1A1)基因多态性与伊立替康联合替吉奥治疗晚期食管鳞癌所致不良反应的关系。方法选取E......
Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a met
...
Irinotecan(CPT-11)is a cytotoxic drug that has wide applicability and usage in cancer treatment.Despite its success,......
目的探讨安罗替尼联合伊立替康三线治疗转移性食管癌的临床疗效及不良反应。方法选取2018年10月至2019年10月安徽省六安市中医院收......
...
【摘要】 目的 评价伊立替康联合FP方案（PIF）和顺铂联合氟尿嘧啶(PF)方案治疗晚期食管癌的疗效及毒副反应。方法 73例确诊晚期食管癌......
目的 探讨贝伐单抗联合FOLFIRI方案化疗用于晚期结直肠癌二线治疗的疗效及安全性.方法 65例既往接受含奥沙利铂化疗的晚期结直肠癌......
目的探讨尿苷二磷酸葡糖醛酸基转移酶1家族肽A(UGT1A)基因多态性与抗肿瘤药伊立替康所致不良反应的相关性,为肿瘤患者个体化用药提......
目的评价尿苷二磷酸葡萄糖醛酸转移酶1A1(UGT1A1)*6基因多态性与伊立替康致3～4级中性粒细胞减少和腹泻的关系。 方法检索PubMed、S......
2例女性患者(例1,61岁;例2, 48岁)因宫颈癌使用伊立替康200 mg联合洛铂50 mg化疗。例1在第2周期化疗后第9天出现腹泻、IV度骨髓抑......
...
A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer acti
Huang-Qin Decoction (HQD) is a classic prescription for diarrhea in Chinese medicine treatment.Recent studies have demon......
３０多年来，５－ＦＵ一直是各期结直肠癌的基本化疗药物。１９９６年６月美国ＦＤＡ提出Ｉｒｉｎｏｔｅｃａｎ对难治性的结直肠癌转移是有效的，与５－ＦＵ相比，Ｉｒｉｎｉｏｔｅｃａｎ对结直肠癌有不同的作用机制，它是一......
目的:探讨按UGT1A1基因多态性分型指导伊立替康治疗肿瘤用药后部分患者的不良反应原因,寻找新的辅助性分子分型标志物.方法:收集本......
目的:观察和分析2种FOLFIRI方案治疗晚期结直肠癌相关不良反应发生情况,以期提高治疗的安全性。方法:应用2种FOLFIRI方案治疗晚期......
目前,临床上使用的新药越来越多,很多新药的不良反应、配伍禁忌等在药物说明书中尚未详细说明,因对新药的了解不全面或使用不当,在......
目的:探讨小细胞肺癌组织中羧酸酯酶-2(CES-2)和拓扑异构酶1(topo1)的表达对伊立替康(CPT-11)联合铂类化疗预后的临床意义。方法:......
Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a variety of tumors. SN-38 ......
Aim: To investigate the effect of breast cancer resistance protein (BCRP) inhibitors and pharmaceutical excipients on re......
,Preliminary results of gentamycin combined with sodium bicarbonate for prevention of irinotecan-ind
The aim of this paper was to observe the clinical effect of gentamycin combined with sodium bicarbonate for the preventi......
Pharmacometabolomics has been already successfully used in toxicity prediction for one specific adverse effect.However i......
目的:观察伊立替康(CPT-11)致小鼠消化与免疫系统不良反应的特点,为CPT-11所致不良反应的预防与治疗提供实验依据。方法:将24只雄......
Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with a
Objective:Several and-programmed cell death 1 (anti-PD-1) antibodies have demonstrated potential efficacy in the treatme......
1例63岁女性结肠癌患者术后采用伊立替康+奥沙利铂化疗方案:首日给予伊立替康200 mg+奥沙利铂200 mg,第8天给予伊立替康160 mg。化......
UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic
AIM: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms......
目的探讨沙利度胺对伊立替康致迟发性腹泻防治效果的影响。方法选取2012年10月至2014年12月来本院就诊接受伊立替康治疗的恶性肿瘤......
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for adva
Background To compare clinical efficacy and toxicity of irinotecan combined with 5-fluorouracil and leucovorin with thos......
Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a met
Background Studies have shown that irinotecan can improve survival in patients with advanced or recurrent gastric cancer......
目的:比较两种不同化疗方案治疗广泛期小细胞肺癌的临床疗效及毒副反应。方法:回顾性分析2010年1月至2013年1月,我院肿瘤科住院治......
Objective:To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cel......
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
ophageal cancer is obviously and it can improve the survival rate of patients, which worthy of clinical application....
Highly sensitive fluorescence quantification of irinotecan in biological fluids with the aid of seco
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Visible-Light-Induced Radical Cascade Cyclization: Synthesis of (20S)-Camptothecin, SN-38 and Irinot
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
目的：观察伊立替康联合顺铂（CPT-11＋CDDP）与伊立替康（CPT-11）单药对进展期胃癌患者化疗的临床疗效。方法：回顾性分析2011年6月至2013年6月......
Objective:To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cel......
目的 比较多西他赛与伊立替康分别联合希罗迭治疗晚期胃癌的近期疗效和不良反应. 方法 65例患者随机分为两组,A组33例应用多西他赛......
目的 观察伊立替康联合氟尿嘧啶治疗晚期大肠癌的主要不良反应,总结急性乙酰胆碱综合征和迟发性腹泻的护理经验.方法 45例病理证实......
ophageal cancer is obviously and it can improve the survival rate of patients, which worthy of clinical application....
